| Name | Title | Contact Details |
|---|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
Campaign for Better Health Care is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Region Ten Community Services Board is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gendex Dental Systems is a Hatfield, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discoveries to inspire the best life for every child and youth. The CHEO Research Institute is a not for profit corporation that connects exceptional talent and technology in pursuit of life-changing research for every child, youth and family in our community and beyond. We inspire trust in our research excellence by being curious, nimble, passionate and equitable.